Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
3 Buy the Dip Stocks to Snap Up Now stocknews.com - Fri Sep 24, 3:43PM CDT

Given current market volatility, buying the dip in fundamentally sound stocks could be a smart move. Thus, the recent dips in quality stocks Corcept Therapeutics (CORT), NextGen Healthcare (NXGN), and...

CORT : 20.29 (-0.98%)
NXGN : 14.53 (-1.29%)
CMT : 11.60 (-0.85%)
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer GlobeNewswire - Fri Sep 17, 7:30AM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 20.29 (-0.98%)
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021 GlobeNewswire - Thu Sep 9, 3:05PM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 20.29 (-0.98%)
SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm GlobeNewswire - Wed Sep 8, 6:00AM CDT

National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. ...

ODT : 3.04 (-1.94%)
AYTU : 2.97 (-1.33%)
EAR : 7.04 (+2.62%)
CORT : 20.29 (-0.98%)
William Guyer to join Corcept as Chief Development Officer GlobeNewswire - Thu Aug 12, 4:00PM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

GILD : 71.19 (-0.70%)
CORT : 20.29 (-0.98%)
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y Zacks - Fri Jul 30, 12:33PM CDT

Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.

BMY : 60.23 (-0.66%)
PFE : 43.94 (-0.57%)
MRK : 73.61 (+0.77%)
CORT : 20.29 (-0.98%)
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates Zacks - Thu Jul 29, 5:35PM CDT

Corcept (CORT) delivered earnings and revenue surprises of 50.00% and 6.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CORT : 20.29 (-0.98%)
Corcept: Q2 Earnings Snapshot AP - Thu Jul 29, 4:23PM CDT

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported second-quarter profit of $26.5 million.

CORT : 20.29 (-0.98%)
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update GlobeNewswire - Thu Jul 29, 3:05PM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating...

CORT : 20.29 (-0.98%)
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase Zacks - Tue Jul 27, 11:38AM CDT

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 64.87 (-0.28%)
RGEN : 323.26 (-0.29%)
CORT : 20.29 (-0.98%)
NBRV : 1.1800 (-2.48%)
Please wait...

Barchart Exclusives

China Completes its Crackdown on Cryptocurrencies Barchart - Fri Sep 24, 9:54AM CDT
Cryptocurrency prices are sinking today after China’s central bank (PBOC) said all crypto-related transactions are illegal. Bitcoin (^BTCUSD ) is down more than -5%, and Ethereum (^ETHUSD ) is down more than -8%. Crypto-currency-related stocks are getting hammered today as well, with Riot Blockchain (RIOT ) down more than -6%,... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot